Price$14.43+0.00 (+0.00%)
03:00 PM07:45 PM
News · 26 weeks61-22%
2025-12-282026-06-21
Mix2690d
- Other11(42%)
- SEC Filings9(35%)
- Insider4(15%)
- Earnings2(8%)
Latest news
25 items- INSIDERChief Technology Officer Moiseyev Gilad converted options into 7,500 units of Ordinary Shares, covered exercise/tax liability with 1,902 units of Ordinary Shares and sold 5,000 units of Ordinary Shares, increasing direct ownership by 1% to 53,098 units (SEC Form 4)4 - Brainsway Ltd. (0001505065) (Issuer)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered LivesBURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol. The announcement comes after a series of favorable policy changes, the latest of which is a recently issued policy covering 2 million members in South Carolina allowing for coverage of SWIFT, in addition to various other increases in Deep TMS coverage for both major depressive disorder (MDD) and obsessive-compulsive disorder (OC
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual MeetingBURLINGTON, Mass. and JERUSALEM, June 09, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the presentation of new prospective 12-month durability data demonstrating sustained clinical benefits following accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Major Depressive Disorder (MDD). The findings were recently presented in a poster by Colleen Hanlon, PhD, Vice President of Medical Affairs for BrainsWay, at the 14th Annual Clinical TMS Society (CTMSS) Meeting which was held on June 4-6, 2026. The data represented outcomes from the first multisite, randomized, controll
- INSIDERChief Scientist Roth Yiftach sold 7,000 units of Ordinary Shares, decreasing direct ownership by 0.65% to 1,072,305 units (SEC Form 4)4 - Brainsway Ltd. (0001505065) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.SCHEDULE 13G/A - Brainsway Ltd. (0001505065) (Subject)
- INSIDERDirector Mitrany Rayten Michal Ety sold 17,980 units of Ordinary Shares, decreasing direct ownership by 59% to 12,500 units (SEC Form 4)4 - Brainsway Ltd. (0001505065) (Issuer)
- INSIDERDirector Mitrany Rayten Michal Ety converted options into 27,500 units of Ordinary Shares and covered exercise/tax liability with 9,520 units of Ordinary Shares, increasing direct ownership by 144% to 30,480 units (SEC Form 4)4 - Brainsway Ltd. (0001505065) (Issuer)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Announces Minority-Stake Investment in Hopemark HealthBURLINGTON, Mass. and JERUSALEM, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with APS Innovations LLC, the parent company of Advanced Psychiatric Management LLC, a management services organization servicing multiple mental health clinics in the greater Chicago area (collectively, "Hopemark Health" or "Hopemark"). Under the terms of the agreement, BrainsWay will invest $1.5 million initially, with potential for an additional $1.5 million via milestone-based
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.SCHEDULE 13G/A - Brainsway Ltd. (0001505065) (Subject)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Reports First Quarter 2026 Financial Results and Operational HighlightsRevenue grew approximately 35% year-over-year to $15.5 million for Q1 2026 Net income increased by over 100% year-over-year to $2.3 million for Q1 2026 Adjusted EBITDA for Q1 of 2026 more than doubled year-over-year to $2.8 million Remaining performance obligations grew 25% year-over-year to approximately $75 million Shipped a record total of 117 Deep TMS Systems, indicating significant demand and further strengthening of relationships with enterprise accounts Reiterates full-year 2026 financial guidance, including revenue of $66 – $68 million, operating income of 13% – 14%, and Adjusted EBITDA of $12 – $14 million Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BrainsWay Ltd.SCHEDULE 13G/A - Brainsway Ltd. (0001505065) (Subject)
- PRBrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026BURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its first quarter 2026 financial results and recent operational highlights before the open of the U.S. financial markets on Wednesday, May 13, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, May 13, 2026Time:8:30 AM Eastern TimeUnited States:1-877-300-8521International:1-412-317-6026Co
- SECSEC Form S-8 filed by BrainsWay Ltd.S-8 - Brainsway Ltd. (0001505065) (Filer)
- SECSEC Form S-8 POS filed by BrainsWay Ltd.S-8 POS - Brainsway Ltd. (0001505065) (Filer)
- SECSEC Form 20-F filed by BrainsWay Ltd.20-F - Brainsway Ltd. (0001505065) (Filer)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
- PRBrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) TherapyBURLINGTON, Mass. and JERUSALEM, April 15, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today highlighted the growing trend across the U.S. payer landscape of coverage policies that allow appropriately trained nurse practitioners to administer Transcranial Magnetic Stimulation (TMS) therapy. A growing number of commercial insurers, Medicare Administrative Contractors (MACs), and government payers now permit psychiatric mental health nurse practitioners (PMHNPs) to administer TMS therapy, including Deep TMS™, when practicing in accordance with app
- PRBrainsWay to Participate in the 25th Annual Needham Virtual Healthcare ConferenceBURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026. Please contact your Needham & Co. representative to request a meeting at the conference. About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulati
- SECSEC Form SCHEDULE 13G filed by BrainsWay Ltd.SCHEDULE 13G - Brainsway Ltd. (0001505065) (Subject)
- SECSEC Form 6-K filed by BrainsWay Ltd.6-K - Brainsway Ltd. (0001505065) (Filer)
BWAY FAQ
7 questionsWhat does BrainsWay Ltd. do?
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying...Where does BWAY stock trade?
BrainsWay Ltd. (BWAY) is listed on NASDAQ.What sector and industry is BWAY in?
BrainsWay Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.When did BrainsWay Ltd. go public?
BrainsWay Ltd. (BWAY) completed its IPO in 2019.What are analysts saying about BWAY?
BrainsWay Ltd. has had 5 recent analyst actions on file. The most recent action was from Raymond James: Mkt Perform on 2023-11-16. Recent price targets range from $1400.00 to $1700.00.What companies are similar to BWAY?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare BWAY side-by-side with any of them on Quantisnow.How can I track BWAY on Quantisnow?
Quantisnow aggregates BrainsWay Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BWAY to receive live email and push alerts on every new disclosure.